Compare Delta Air Lines, Inc. (DAL) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Delta Air Lines, Inc. vs GeneDx Holdings Corp — how do they compare? Delta Air Lines, Inc. trades at $83.37 (market cap $54.56B), while GeneDx Holdings Corp trades at $67.6 (market cap $2.04B). The key difference: Delta Air Lines, Inc. is far larger — about 26.7× GeneDx Holdings Corp's market cap, and Delta Air Lines, Inc. pays a 1.04% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Delta Air Lines, Inc. for 97 Days and GeneDx Holdings Corp for 19 Days on average.
| DAL | WGS | |
|---|---|---|
Market Cap | $54.56B | $2.04B |
Volume | 6,532,736 | 659,215 |
Sector | Industrials | Health |
52-Week High | $93.66 | $167.51 |
52-Week Low | $55.65 | $34.51 |
Typical Hold Time | 97 Days | 19 Days |
Enterprise Value | $69.88B | $2.08B |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Delta Air Lines (DAL) trades at $82.97, down 0.82% on the day, with technical indicators showing bearish momentum despite strong fundamentals. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue growth has been steady, reaching $63.36 billion in 2025, while profitability metrics remain solid with a 5.78% net income margin and 20.12% ROE. Analyst sentiment remains overwhelmingly positive with 82% buy ratings and a $103.36 consensus price target representing 25% upside potential.
DAL presents a compelling investment case with attractive valuation multiples (P/E of 13.76, P/S of 0.8) and strong cash flow generation, though near-term headwinds include fuel cost volatility and competitive pressures. The stock's technical weakness contrasts with fundamental strength, creating potential opportunity for patient investors. Key risks include oil price sensitivity and execution challenges in maintaining premium customer loyalty against aggressive competitor tactics.
GeneDx (WGS) trades at $68.53, down 4.18% today amid bearish technical signals despite recent positive earnings surprises. The stock shows mixed fundamentals with strong revenue growth to $454M in 2026 but negative profitability metrics including -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target representing 18% upside potential.
The investment case balances strong analyst support and genomic testing market growth against persistent profitability challenges and negative cash flow trends. Key catalysts include Q3 2026 earnings due soon and continued execution on operational improvements, while risks center on margin recovery timeline and competitive pressures in the rapidly evolving genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
